Delivering Advanced Prostate Cancer Therapy in a Virtual Urology Clinic
Urology
Curriculum:
Teaching through a Window: Optimal Management of Advanced Prostate Cancer in a Urology Practice
Teaching through a Window: Optimal Management of Advanced Prostate Cancer in a Urology Practice
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
September 28, 2017
September 28, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Urologists, advanced practice nurses, and others working in urology clinics
Relevant Terms:
Prostate cancer; oral therapy; infusion therapy; urology practice
David M. Albala, MD
David M. Albala, MD
Medical Director, Co-Director of Research
Associated Medical Professionals
Syracuse, NY
Bio
Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. After 10 years, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 180 publications in peer-reviewed journals and has authored three textbooks in endourology and one in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. He serves on the editorial board for the, Journal of Endourology, Medical Reviews in Urology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. At the present time he is Chief of Urology at Crouse Hospital in Syracuse, New York and Medical Director for Associated Medical Professionals (a group of 29 urologists). He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 16 fellows in endourology and advanced robotic surgery. In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.
Neal Shore, MD, FACS
Neal Shore, MD, FACS
Director, CPI
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Bio
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Mark Garzotto, MD
Mark Garzotto, MD - External Reviewer
Associate Professor of Urology and Radiation Oncology
Oregon Health & Science University
Director, Urologic Oncology
Portland VAMC
Portland, OR
Bio
Dr. Garzotto is a Professor of Urology and Radiation Oncology at Oregon Health & Science University and the Director of Urologic Oncology at the Portland VA Medical Center. He completed his residency at the University of Florida and a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. He is the Director of Urologic Oncology at the Portland VA Medical Center and is the current Chairman of the Urology Surgical Advisory Board for the VA National Surgical Office. He is an expert in the development of diagnostic strategies for prostate cancer. He is the principal investigator on several trials for high-risk and advanced prostate cancer. He serves on the executive committee for several Phase III Cooperative Group trials for the Southwest oncology Group, RTOG and the Veterans Administration. He specializes in the surgical management of prostate cancer with expertise in nerve-sparing techniques. He has published extensively in national and international journals and serves as an Associate Editor and peer-reviewer for several internationally recognized journals.
| 1. | Review current practices and treatment options for advanced prostate cancer | 2. | Apply current guideline recommendations for chemotherapy, immunotherapy, bone-targeted therapy, and androgen suppression therapy in patients with advanced prostate cancer |
| 3. | Recognize the quality of life issues affecting patients with advanced prostate cancer | 4. | Outline the role of the urologist in the development of advanced prostate cancer centers of excellence |
| 1. | Review current practices and treatment options for advanced prostate cancer |
| 2. | Apply current guideline recommendations for chemotherapy, immunotherapy, bone-targeted therapy, and androgen suppression therapy in patients with advanced prostate cancer |
| 3. | Recognize the quality of life issues affecting patients with advanced prostate cancer |
| 4. | Outline the role of the urologist in the development of advanced prostate cancer centers of excellence |
This activity was launched on October 3, 2017 and will expire on October 3, 2018.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of urologists, nurse practitioners (NPs), and physician assistants (PAs) who practice in a urologic setting.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of urologists, nurse practitioners (NPs), and physician assistants (PAs) who practice in a urologic setting.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Neal Shore, MD, FACS | Dr Shore has served on a Speakers Bureau and has received funds for contracted research from Bayer, Astellas, Janssen, and Sanofi. He has also served on an Advisory Board and has received funds for contracted research from AbbVie, Amgen, Astellas, Bayer,Ferring, Janssen, Pfizer, Sanofi, and Tolmar. |
| David M. Albala, MD | Dr. Albala has served on a Speakers Bureau for Genomic Health and Myriad. He has also served on an Advisory Board and has received funds for contracted research from Cellanyx Diagnostics. |
| Mark Garzotto, MD | Dr. Garzotto has received funds for contracted research from Merck, Astellas/Pfizer, Dendreon, and Genomic Health. |
OTHER CONTRIBUTORS Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME defined commercial interest.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by an educational grant from Sanofi Genzyme.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
